Following on from information provided to NICE by the company in March 2018, the appraisal of Eltrombopag for untreated severe aplastic anaemia [ID1198] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1198 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in March 2018, the appraisal of Eltrombopag for untreated severe aplastic anaemia [ID1198] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 13 March 2018 | Suspended. The company has informed NICE that they will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal whilst we consider the next steps |
For further information on our processes and methods, please see our CHTE processes and methods manual